In kidney, 111In-labeled 4-arm DOTA-α-MSH provided significantly lower average accumulation (1.38-fold) than 111In-labeled 3-arm DOTA-α-MSH at all acquisition time points, whereas 111In-labeled 4-arm DOTA-α-MSH provided significantly higher average accumulation (1.32-fold) than 111In-labeled 3-arm DOTA-α-MSH in B16-F1 melanoma. The gene discussed is STAMBP; the disease is melanoma.